Malta - English - Medicines Authority

tecnimede - sociedade tecnico-medicinal sa rua da tapada grande, no 2 abrunheira 2710-089 sintra, portugal - ambroxol hydrochloride - prolonged-release capsule - ambroxol hydrochloride 120 mg - cough and cold preparations

Philippines - English - FDA (Food And Drug Administration)

tecnimede-sociedade tecnico medicinal, s.a.; importer: ambicare pharmaceuticals inc.; distributor: ambicare pharmaceuticals inc. - topiramate - film-coated tablet - 25 mg

European Union - English - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin - diabetes mellitus, type 2 - drugs used in diabetes, dipeptidyl peptidase 4 (dpp-4) inhibitors - vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).

European Union - English - EMA (European Medicines Agency)

takeda pharma a/s - azilsartan medoxomil - hypertension - agents acting on the renin-angiotensin system - edarbi is indicated for the treatment of essential hypertension in adults.

European Union - English - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin benzoate, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

European Union - English - EMA (European Medicines Agency)

recordati ireland ltd - silodosin - prostatic hyperplasia - urologicals - treatment of the signs and symptoms of benign prostatic hyperplasia (bph)

Israel - English - Ministry of Health

bioavenir ltd, israel - ciprofloxacin - solution for infusion - ciprofloxacin 200 mg / 100 ml - ciprofloxacin - ciprofloxacin - * adults :broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens.* children and adolescents:• broncho-pulmonary infections in cystic fibrosis caused by pseudomonas aeruginosa• complicated urinary tract infections and pyelonephritis• inhalation anthrax (post-exposure prophylaxis and curative treatment)ciprofloxacin may also be used to treat severe infections in children and adolescents when there is no otheralternative .treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents

European Union - English - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin, pioglitazone - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - incresync is indicated as a second- or third-line treatment in adult patients aged 18 years and older with type-2 diabetes mellitus: , as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance;, in combination with metformin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on their maximal tolerated dose of metformin and pioglitazone. , in addition, incresync can be used to replace separate tablets of alogliptin and pioglitazone in those adult patients aged 18 years and older with type-2 diabetes mellitus already being treated with this combination. after initiation of therapy with incresync, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, incresync should be discontinued. in light of potential risks with prolonged pioglitazone therapy, prescribers should confirm at subsequent routine reviews that the benefit of incresync is maintained (see section 4.4).,

Ireland - English - HPRA (Health Products Regulatory Authority)

takeda pharma a/s - azilsartan medoxomil potassium; chlortalidone - film-coated tablet - 40/12.5 milligram(s) - angiotensin ii antagonists and diuretics; angiotensin ii antagonists and diuretics